SIRT2は,病理性心筋縮における心臓保護性デアセチラーゼとして作用する
Xiaoqiang Tang1, Xiao-Feng Chen1, Nan-Yu Wang1
1Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (X.T., X.-F.C., N.-Y.W., X.-M.W., S.-T.L., W.Z., X.Z., D.-L.H., Z.-Q.Z., H.-Z.C., D.-P.L.).
Circulation
|September 27, 2017
まとめ
Sirtuin 2 (SIRT2) タンパク質は,心不全でダウンレギュレーションされます. SIRT2の喪失は心臓の過剰増殖を悪化させ,その過剰発現は心臓を保護する. SIRT2は心臓不全の潜在的治療標的である.
科学分野:
- 心血管生物学
- 病気 の 分子 機構
- 老化に関する研究
背景:
- 心臓不全の主要な危険因子である.
- 特に老化やストレスで心臓の縮を起こすメカニズムは完全に理解されていません.
- 心臓縮におけるシルトゥイン2 (SIRT2) の役割は調査が必要である.
研究 の 目的:
- SIRT2が老化に関連した心筋縮における役割を調査する.
- アンジオテンシンII (Ang II) 誘発の心臓高縮におけるSIRT2の機能を調べる.
- SIRT2が心筋縮に影響を与える分子メカニズムを解明する.
主な方法:
- 野生型のSirt2ノックアウトと心臓特異のSIRT2トランスジェニックマウスを使用した.
- 高齢化とAng II輸液による誘発性心筋縮
- SIRT2との相互作用を評価するためにメトホルミンを投与した.
- 評価された心筋縮,繊維症,および機能.
主要な成果:
- SIRT2発現が低下した.
- Sirt2 ノックアウトは心臓の縮と線維症を悪化させ,心臓の機能を低下させた.
- SIRT2過剰発現は,Ang II誘発の心筋縮および線維症から保護されます.
- SIRT2は肝臓キナーゼB1 (LKB1) を脱酸化することによってAMP活性化タンパク質キナーゼ (AMPK) を活性化します.
- SIRT2の喪失はメトホルミンの心臓保護効果を低下させた.
結論:
- SIRT2はLKB1の脱酸化によってAMPKを活性化し,心臓の健康を促進する.
- SIRT2濃度の低下は,老化およびAng II誘発の心筋縮に寄与する.
- SIRT2は,心筋縮および心不全の治療における潜在的な治療標的である.
関連する概念動画
Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
Cardiomyopathy II: Dilated Cardiomyopathy
634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
Cardiomyopathy V: Interprofessional Care
506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506

